11/29/2016 | CV | Aegerion 2% convertibles now convertible for Novelion stock
|
6/16/2016 | CV | Aegerion 2% convertibles to be convertible into QLT shares post-merger
|
5/2/2016 | PP | QLT scraps $20 million private offer after InSite deal falls through
|
1/30/2009 | SS | QLT buys back $50 million of stock in Dutch auction tender
|
1/27/2009 | SS | QLT to buy back 26.8% of its shares in completed tender offer
|
1/15/2009 | SS | QLT tender offer extended to Jan. 26
|
1/9/2009 | SS | Mackenzie Financial says it has 12.67% equity stake in QLT
|
12/22/2008 | SS | NB Public Equity reports passive stake of 7% in QLT
|
12/19/2008 | SS | QLT shareholder West Coast drops stake to 5.9%
|
12/5/2008 | SS | QLT begins tender offer for up to $50 million of its common shares
|
12/1/2008 | SS | QLT begins modified Dutch auction tender offer for up to $50 million of common stock
|
10/28/2008 | SS | QLT investor may be prepping for activism
|
9/15/2008 | CV | QLT redeems all $172.5 million of its 3% convertibles
|
8/11/2008 | CV | QLT calls all $172.5 million of its 3% convertibles
|
1/17/2008 | CV | QLT plans to use asset sale proceeds to fund upcoming 3% convertibles put
|
1/17/2008 | SS | Market Commentary: Midwest Air deal raises monopoly issues in Milwaukee; Quebecor, with rescue package, returns to lenders
|
12/11/2007 | SS | QLT appoints financial adviser in review of strategic options
|
12/3/2007 | SS | Jana Partners reduces stake in QLT to less than 5%
|
10/9/2007 | SS | Market Commentary: Miramar Mining stock digs Newmont takeover bid; QLT shares slip on plan to buy ForSight
|
8/10/2007 | SS | Jana Partners sells shares of QLT, keeps 9.9% stake
|
11/8/2006 | BT | Merrill has QLT at neutral
|
11/7/2006 | BT | QLT at neutral by Merrill on jury decision
|
10/27/2006 | BT | QLT at neutral by Merrill
|
10/27/2006 | BT | QLT still at sector perform by RBC
|
10/26/2006 | BT | QLT plans to make ocular business primary therapeutic area, cut R&D costs
|
10/20/2006 | BT | QLT kept at sector perform by RBC
|
10/19/2006 | BT | QLT at neutral by Merrill
|
10/13/2006 | BT | QLT gets neutral rating from Merrill
|
9/12/2006 | BT | Merrill keeps QLT at neutral
|
9/11/2006 | BT | QLT to cancel 13 million shares in preliminary results of tender offer
|
8/3/2006 | BT | QLT launches tender offer for up to 13 million common shares
|
7/28/2006 | BT | QLT rated at sector perform by RBC
|
7/27/2006 | BT | QLT says second-quarter revenues down 19.8% at $47.8 million, announces tender offer
|
7/18/2006 | BT | RBC gives QLT sector perform rating
|
7/17/2006 | BT | Merrill has QLT at neutral
|
6/5/2006 | BT | QLT at neutral by Merrill
|
5/19/2006 | BT | RBC rates QLT at sector perform
|
5/19/2006 | BT | QLT at neutral by Merrill
|
5/18/2006 | BT | Toxicology study delays QLT's phase 2a Atrigel/octreotide program in acromegaly
|
5/10/2006 | BT | QLT at neutral by Merrill
|
4/28/2006 | BT | QLT at neutral by Merrill
|
4/27/2006 | BT | QLT first-quarter revenues of $50.4 million down 18.3% from previous year
|
4/24/2006 | BT | QLT's neutral rating unchanged by Merrill
|
4/19/2006 | BT | Merrill keeps QLT at neutral
|
4/10/2006 | BT | QLT kept at neutral by Merrill
|
4/6/2006 | BT | QLT: Court of Appeals grants stay of injunction against Eligard sales
|
4/5/2006 | BT | QLT signs development, licensing deal with Retinagenix for ocular synthetic retinoid program
|
3/7/2006 | BT | Injunction suspends QLT, Sanofi sales of Eligard in United States until TAP patent expires
|
3/7/2006 | BT | QLT kept at neutral by Merrill
|
2/28/2006 | BT | CollaGenex extends marketing pact with QLT, raises royalty payments
|
2/28/2006 | BT | QLT intends to appeal U.S. Eligard injunction
|
2/28/2006 | BT | QLT at neutral by Merrill
|
2/27/2006 | BT | QLT names Robert Butchofsky president, CEO
|
2/23/2006 | BT | QLT keeps Merrill's neutral rating
|
2/22/2006 | BT | Market Commentary: Axcan annihilated; Lexicon lifted; Advanced Magnetics draws interest; CombiMatrix climbs
|
2/22/2006 | CV | Market Commentary: MeriStar dives on buyout news; QLT gains despite wider losses; Amgen strong
|
2/14/2006 | BT | Merrilll keeps QLT at neutral
|
2/14/2006 | BT | QLT says phase 2 lemuteporfin-injectable trial failed to meet primary endpoint
|
1/23/2006 | BT | QLT says it plans to appeal court's decision in Eligard patent case against TAP
|
1/23/2006 | BT | Merrill maintains QLT at neutral
|
1/19/2006 | BT | QLT maintained at neutral by Merrill
|
1/17/2006 | BT | QLT maintained by Merrill at neutral
|
12/8/2005 | BT | QLT to narrow focus, cut staff by up to 46%, reduce expenses 20% in response to Visudyne sales drop
|
12/8/2005 | BT | QLT maintained by Merrill at neutral
|
12/8/2005 | BT | Market Commentary: Voyager rejigs IPO talk, cuts size; QLT plunges on severe cutbacks; LabCorp up sharply on buyback
|
12/6/2005 | BT | Merrill maintains QLT at neutral
|
11/8/2005 | BT | Merrill Lynch maintains QLT at neutral
|
10/28/2005 | BT | Merrill Lynch maintains QLT's neutral rating
|
9/26/2005 | BT | Market Commentary: Eye drug names viewed in mixed fashion; Ligand gains on hopes of sale; Endo plunges on secondary
|
9/21/2005 | BT | QLT maintained by Merrill Lynch at neutral
|
9/21/2005 | BT | Market Commentary: Nektar, Cyberonics pitch converts; QLT spirals; Chiron players shift to 2.75s; Alkermes stumbles
|
8/22/2005 | BT | Market Commentary: Alpharma gains on deal chatter; OSI plunges, Eyetech up on deal; QLT higher; Acambis slides
|
7/29/2005 | BT | QLT maintained by Merrill at neutral
|
7/19/2005 | BT | QLT downgraded by Merrill Lynch to neutral
|
7/19/2005 | BT | Market Commentary: Able bankruptcy sparks buying by restructuring specialists; Amgen a blowout; Genentech weighs on QLT
|
7/14/2005 | BT | QLT maintained by Merrill at buy
|
7/13/2005 | BT | QLT maintained by Merrill at buy
|
7/6/2005 | BT | QLT retained by Merrill at buy
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|
8/27/2004 | CV | Market Commentary: Southern Union up as Enron auction nears; Red Hat gains; QLT retreats; Delta steady
|
8/26/2004 | CV | Market Commentary: QLT gains as competing drug approval seen risky; Gap, apparel issues off; Delta steady
|
6/14/2004 | CV | Market Commentary: QLT convertible on swap loses about 2.5 points on Atrix buy; Four Seasons launches, fades
|
8/19/2003 | CV | Market Commentary: InVision deal scrapped amid summer lull, officially citing adverse "market conditions"
|
8/14/2003 | CV | QLT greenshoe exercised, raising convertibles to $172.5 million
|
8/13/2003 | CV | Market Commentary: New deal train chugs slowly along with string of small deals; dividend risk still high profile
|
8/12/2003 | CV | New Issue: QLT $150 million convertible yields 3.0%, up 30%
|
8/12/2003 | CV | Market Commentary: Reliant converts plunge 16.25 points as broader market gains; Cadence deal reoffered at 98
|
8/11/2003 | CV | QLT $150 million convertible talked at 3.0%, up 30-35%
|
8/11/2003 | CV | Market Commentary: Trading quiet ahead of Fed; three deals on tap after close, with slim gray market activity
|